Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.44 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RPA1 | P27694 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497315 | 0.86 | SMN1; SMN2 (0.50) | ALKBH5MLLT3MLLT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30504030 | 0.83 | KDM4E (0.51) | KDM4EMLLT3MLLT1 | |
| SCHEMBL9672296 | 0.83 | MLLT3 (0.61) | KDM4EMLLT3MLLT1 | |
| SCHEMBL5509095 | 0.83 | KDM4E (0.51) | KDM4EMLLT3MLLT1 | |
| SCHEMBL2498082 | 0.83 | MLLT3 (0.44) | KDM4EALKBH5MLLT3MLLT1SMN1; SMN2 | |
| SCHEMBL12191229 | 0.83 | NOTUM (0.43) | KDM4EALKBH5MLLT3MLLT1ALDH1A1 | |
| SCHEMBL69486 | 0.82 | KDM4E (0.55) | KDM4E | |
| SCHEMBL4425145 | 0.82 | KDM4E (0.50) | KDM4EMLLT3MLLT1 | |
| SCHEMBL12191233 | 0.82 | KDM4E (0.57) | KDM4EALKBH5RPA1 | |
| SCHEMBL1879655 | 0.82 | KDM4E (0.50) | KDM4EMLLT3MLLT1RPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101798298-B | Imidazole derivatives | HOFFMANN LA ROCHE | 2013-01-09 | — | — | CN | disclosed |
| US-7939556-B2 | Imidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-05-10 | — | — | US | disclosed |
| US-7858649-B2 | Imidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-28 | — | — | US | disclosed |
| US-7858649-B2 | Imidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-28 | — | — | US | disclosed |
| US-7858649-B2 | Imidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-28 | — | — | US | disclosed |
| CN-101798298-A | Imdazole derivatives | HOFFMANN LA ROCHE | 2010-08-11 | — | — | CN | disclosed |
| CN-1489580-B | Imidazole derivatives | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| US-20090209597-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA ALPHA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| US-20090163566-A1 | Imidazole Derivatives and their use for Modulating the Gabaa Receptor Complex | NEUROSEARCH A/S (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163566-A1 | Imidazole Derivatives and their use for Modulating the Gabaa Receptor Complex | NEUROSEARCH A/S (DE) | 2009-06-25 | — | — | US | disclosed |
| WO-2007042544-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
| CN-1489580-A | Imidazole derivatives | - | 2004-04-14 | — | — | CN | disclosed |
| US-6683097-B2 | AFFINITY TO NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR SUBTYPE SELECTIVE BLOCKERS; MEDIATING PROCESSES UNDERLYING DEVELOPMENT OF CENTRAL NERVOUS SYSTEM AS WELL AS LEARNING AND MEMORY FORMATION | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667335-B2 | NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | disclosed |
| EP-1358165-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030187268-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6610723-B2 | Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020151715-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002060877-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | GRIN1, GRIN2B, GRIN3B | KDM4E 1141/4885ALKBH5 3440/4885MLLT3 3634/4885 |
| US-20020151715-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | KDM4E 1192/4885ALKBH5 3588/4885MLLT3 3543/4885 |
| US-20090209597-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA ALPHA RECEPTOR COMPLEX | GABRB1, GABRB2, GABRB3 | KDM4E 2635/4885ALKBH5 4764/4885MLLT3 3838/4885 |
| US-20090163566-A1 | Imidazole Derivatives and their use for Modulating the Gabaa Receptor Complex | GABRB2, GABRB1, GABRB3 | KDM4E 3121/4885ALKBH5 4744/4885MLLT3 3398/4885 |
| US-20030187268-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | KDM4E 1192/4885ALKBH5 3588/4885MLLT3 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.